Payment overview · 2025
General Payments
$1,450.69
80 reported records · 19 companies
Healthcare provider profile · identity verified
Bruce B Brown, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · UNION CITY, TN · NPI 1942280243
Verified facts
What the public records show
CMS Open Payments records show Bruce B Brown, M.D. received $1,450.69 in general payments during 2025 across 80 reported records.
Novo Nordisk Inc accounted for 22.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 28 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Mounjaro, Ozempic, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported HUMIRA as an associated drug or biological on 1828 records involving 689 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Humira by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 83 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Trelegy Ellipta by this doctor in 2024.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 24 records involving 23 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 83 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 75 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Rybelsus by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Nuedexta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 233 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $320.00 | 22.1% | 22 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $200.76 | 13.8% | 7 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $138.17 | 9.5% | 8 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $120.84 | 8.3% | 7 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $102.62 | 7.1% | 5 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $92.54 | 6.4% | 5 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $73.59 | 5.1% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $71.96 | 5.0% | 5 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $45.23 | 3.1% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $43.09 | 3.0% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $39.20 | 2.7% | 2 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $37.00 | 2.5% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $34.61 | 2.4% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $33.89 | 2.3% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $23.80 | 1.6% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$21.28 | 1.5% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $20.59 | 1.4% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.61 | 1.2% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $13.91 | 1.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,450.69 | 80 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $231.89 | 17 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $160.32 | 4 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $142.43 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $138.17 | 8 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $104.49 | 6 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $102.62 | 5 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $92.54 | 5 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $90.25 | 6 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $88.11 | 5 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $74.85 | 4 | 2025 |
Source payment records
|
|||||
| TREMFYA Normalized: tremfya |
Drug | Janssen Biotech, Inc. | $73.59 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $58.30 | 4 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $58.30 | 4 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $45.23 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $43.09 | 3 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $38.61 | 2 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $37.00 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $36.49 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $34.61 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $33.89 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $23.80 | 1 | 2025 |
Source payment records
|
|||||
| INTERSTIM Normalized: interstim |
Device | Medtronic, Inc. | $21.28 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $20.59 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $17.61 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $16.35 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $13.91 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $13.91 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $13.66 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 233 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 64 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 83 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 75 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 58 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | HUMIRA open payments reported associated product |
CMS Open Payments — General Payments 1828 supporting records · 689 recipient NPIs · example record 1201353784 |
Humira · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
50 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
64 | 13 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
83 | 21 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
58 | 11 |
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 24 supporting records · 23 recipient NPIs · example record 1174259978 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
83 | 21 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
65 | 13 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
75 | 13 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
14 | 12 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
233 | 38 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 682 | 142 |
| Levothyroxine Sodium | Levothyroxine Sodium | 477 | 90 |
| Pantoprazole Sodium | Pantoprazole Sodium | 432 | 80 |
| Lisinopril | Lisinopril | 410 | 78 |
| Furosemide | Furosemide | 377 | 69 |
| Potassium Chloride | Potassium Chloride | 376 | 85 |
| Omeprazole | Omeprazole | 373 | 82 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 320 | 77 |
| Amlodipine Besylate | Amlodipine Besylate | 314 | 59 |
| Escitalopram Oxalate | Escitalopram Oxalate | 291 | 50 |
| Tamsulosin Hcl | Tamsulosin Hcl | 261 | 54 |
| Trazodone Hcl | Trazodone Hcl | 242 | 39 |
| Eliquis | Apixaban | 233 | 38 |
| Divalproex Sodium | Divalproex Sodium | 232 | 24 |
| Lorazepam | Lorazepam | 227 | 38 |
| Metformin Hcl | Metformin Hcl | 227 | 54 |
| Metoprolol Tartrate | Metoprolol Tartrate | 222 | 38 |
| Metoprolol Succinate | Metoprolol Succinate | 186 | 45 |
| Clopidogrel | Clopidogrel Bisulfate | 184 | 39 |
| Pravastatin Sodium | Pravastatin Sodium | 184 | 34 |
| Famotidine | Famotidine | 181 | 39 |
| Carvedilol | Carvedilol | 179 | 35 |
| Losartan Potassium | Losartan Potassium | 167 | 40 |
| Hydrochlorothiazide | Hydrochlorothiazide | 166 | 44 |
| Sertraline Hcl | Sertraline Hcl | 160 | 31 |
| Donepezil Hcl | Donepezil Hcl | 158 | 29 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 158 | 44 |
| Gabapentin | Gabapentin | 157 | 45 |
| Meloxicam | Meloxicam | 155 | 34 |
| Paroxetine Hcl | Paroxetine Hcl | 152 | 26 |
| Simvastatin | Simvastatin | 145 | 38 |
| Buspirone Hcl | Buspirone Hcl | 143 | 27 |
| Allopurinol | Allopurinol | 140 | 31 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 132 | 34 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 129 | 27 |
| Memantine Hcl | Memantine Hcl | 127 | 16 |
| Duloxetine Hcl | Duloxetine Hcl | 126 | 23 |
| Hydralazine Hcl | Hydralazine Hcl | 123 | 22 |
| Alprazolam | Alprazolam | 120 | 24 |
| Mirtazapine | Mirtazapine | 111 | 17 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 104 | 41 |
| Nabumetone | Nabumetone | 102 | 20 |
| Lidocaine Hcl | Lidocaine Hcl | 98 | 35 |
| Torsemide | Torsemide | 95 | 17 |
| Januvia | Sitagliptin Phosphate | 94 | 14 |
| Diclofenac Sodium | Diclofenac Sodium | 91 | 25 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 91 | 26 |
| Tizanidine Hcl | Tizanidine Hcl | 89 | 23 |
| Spironolactone | Spironolactone | 88 | 15 |
| Glimepiride | Glimepiride | 86 | 23 |
| Quetiapine Fumarate | Quetiapine Fumarate | 86 | 14 |
| Jardiance | Empagliflozin | 83 | 21 |
| Lamotrigine | Lamotrigine | 80 | 12 |
| Metformin Hcl Er | Metformin Hcl | 79 | 17 |
| Zolpidem Tartrate | Zolpidem Tartrate | 79 | 14 |
| Montelukast Sodium | Montelukast Sodium | 77 | 17 |
| Ceftriaxone | Ceftriaxone Sodium | 76 | 32 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 76 | 16 |
| Ozempic | Semaglutide | 75 | 13 |
| Tramadol Hcl | Tramadol Hcl | 71 | 27 |
| Lovastatin | Lovastatin | 70 | 14 |
| Etodolac | Etodolac | 69 | 23 |
| Alendronate Sodium | Alendronate Sodium | 68 | 16 |
| Dicyclomine Hcl | Dicyclomine Hcl | 68 | 12 |
| Pioglitazone Hcl | Pioglitazone Hcl | 67 | 20 |
| Ondansetron Hcl | Ondansetron Hcl | 66 | 19 |
| Naproxen | Naproxen | 65 | 16 |
| Trulicity | Dulaglutide | 65 | 13 |
| Farxiga | Dapagliflozin Propanediol | 64 | 13 |
| Ibuprofen | Ibuprofen | 64 | 19 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 63 | 26 |
| Glipizide | Glipizide | 62 | 17 |
| Prednisone | Prednisone | 62 | 22 |
| Fenofibrate | Fenofibrate | 60 | 18 |
| Benztropine Mesylate | Benztropine Mesylate | 59 | suppressed |
| Pregabalin | Pregabalin | 59 | 13 |
| Clonidine Hcl | Clonidine Hcl | 58 | 14 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 58 | 11 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 58 | 11 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 57 | 19 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 56 | 15 |
| Ezetimibe | Ezetimibe | 55 | 16 |
| Benazepril Hcl | Benazepril Hcl | 51 | 13 |
| Lansoprazole | Lansoprazole | 51 | suppressed |
| Nifedipine Er | Nifedipine | 51 | 13 |
| Diazepam | Diazepam | 50 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 50 | 11 |
| Fluticasone Propionate | Fluticasone Propionate | 50 | 19 |
| Synthroid | Levothyroxine Sodium | 50 | suppressed |
| Atenolol | Atenolol | 48 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 48 | 11 |
| Warfarin Sodium | Warfarin Sodium | 48 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 47 | suppressed |
| Felodipine Er | Felodipine | 47 | suppressed |
| Lactulose | Lactulose | 46 | 11 |
| Levetiracetam | Levetiracetam | 45 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 45 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 45 | 25 |
| Valsartan | Valsartan | 45 | suppressed |
| Azithromycin | Azithromycin | 44 | 24 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 44 | 14 |
| Metoclopramide Hcl | Metoclopramide Hcl | 44 | 11 |
| Clonazepam | Clonazepam | 43 | suppressed |
| Digoxin | Digoxin | 43 | suppressed |
| Olanzapine | Olanzapine | 43 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 42 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 42 | 24 |
| Eszopiclone | Eszopiclone | 41 | suppressed |
| Linzess | Linaclotide | 41 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 38 | 16 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 38 | 16 |
| Primidone | Primidone | 38 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 37 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 36 | 11 |
| Celecoxib | Celecoxib | 36 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 36 | 15 |
| Promethazine Hcl | Promethazine Hcl | 36 | 16 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 34 | 11 |
| Mupirocin | Mupirocin | 34 | 21 |
| Terazosin Hcl | Terazosin Hcl | 34 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 34 | suppressed |
| Cephalexin | Cephalexin | 33 | 21 |
| Estradiol | Estradiol | 33 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 33 | suppressed |
| Risperidone | Risperidone | 33 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 33 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 32 | suppressed |
| Galantamine Er | Galantamine Hbr | 32 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 32 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 32 | suppressed |
| Verapamil Er | Verapamil Hcl | 32 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 31 | suppressed |
| Methocarbamol | Methocarbamol | 30 | suppressed |
| Nadolol | Nadolol | 30 | suppressed |
| Nystop | Nystatin | 30 | 14 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 29 | suppressed |
| Irbesartan | Irbesartan | 29 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 29 | suppressed |
| Ramipril | Ramipril | 29 | suppressed |
| Chlorthalidone | Chlorthalidone | 28 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 28 | suppressed |
| Amiloride Hcl | Amiloride Hcl | 27 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 27 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 27 | 20 |
| Glipizide Er | Glipizide | 27 | suppressed |
| Haloperidol | Haloperidol | 27 | suppressed |
| Xarelto | Rivaroxaban | 27 | suppressed |
| Aripiprazole | Aripiprazole | 26 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 26 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 26 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 26 | suppressed |
| Levofloxacin | Levofloxacin | 25 | 20 |
| Propranolol Hcl Er | Propranolol Hcl | 25 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 24 | suppressed |
| Humalog | Insulin Lispro | 24 | suppressed |
| Tradjenta | Linagliptin | 24 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 23 | suppressed |
| Rybelsus | Semaglutide | 23 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 22 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 22 | suppressed |
| Fluconazole | Fluconazole | 22 | 16 |
| Methotrexate | Methotrexate Sodium | 22 | suppressed |
| Novolog | Insulin Aspart | 22 | suppressed |
| Sulindac | Sulindac | 22 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Admelog | Insulin Lispro | 20 | suppressed |
| Amoxicillin | Amoxicillin | 20 | 14 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 20 | 16 |
| Cefadroxil | Cefadroxil | 20 | 17 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 20 | suppressed |
| Klor-Con M20 | Potassium Chloride | 20 | suppressed |
| Rivastigmine | Rivastigmine | 20 | suppressed |
| Scopolamine | Scopolamine | 20 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 19 | suppressed |
| Levemir | Insulin Detemir | 19 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 19 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 19 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 19 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 19 | suppressed |
| Baclofen | Baclofen | 18 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 18 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 18 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 18 | suppressed |
| Nystatin | Nystatin | 18 | 14 |
| Prasugrel Hcl | Prasugrel Hcl | 18 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 18 | suppressed |
| Sotalol | Sotalol Hcl | 18 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 18 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 18 | suppressed |
| Cilostazol | Cilostazol | 17 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 17 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 17 | suppressed |
| Nateglinide | Nateglinide | 17 | suppressed |
| Nitroglycerin | Nitroglycerin | 17 | 11 |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 17 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 17 | suppressed |
| Dexamethasone Sodium Phosphate | Dexamethasone Sodium Phosphate | 16 | 11 |
| Galantamine Hbr | Galantamine Hbr | 16 | suppressed |
| Latanoprost | Latanoprost | 16 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 16 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 16 | 13 |
| Santyl | Collagenase Clostridium Hist. | 16 | suppressed |
| Topiramate | Topiramate | 16 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Acyclovir | Acyclovir | 15 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 15 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 15 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 15 | suppressed |
| Erythromycin | Erythromycin Base | 15 | 11 |
| Febuxostat | Febuxostat | 15 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 15 | suppressed |
| Mounjaro | Tirzepatide | 15 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 15 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 14 | 12 |
| Azelastine Hcl | Azelastine Hcl | 14 | suppressed |
| Bumetanide | Bumetanide | 14 | suppressed |
| Glucagon Emergency Kit | Glucagon | 14 | suppressed |
| Methimazole | Methimazole | 14 | suppressed |
| Metolazone | Metolazone | 14 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 14 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 14 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 14 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 13 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 13 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 13 | suppressed |
| Finasteride | Finasteride | 13 | suppressed |
| Gemfibrozil | Gemfibrozil | 13 | suppressed |
| Haloperidol Lactate | Haloperidol Lactate | 13 | suppressed |
| Humira | Adalimumab | 13 | suppressed |
| Lidocaine | Lidocaine | 13 | suppressed |
| Phenobarbital | Phenobarbital | 13 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 13 | suppressed |
| Carbamazepine | Carbamazepine | 12 | suppressed |
| Cefdinir | Cefdinir | 12 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 12 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 12 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 12 | suppressed |
| Betamethasone Valerate | Betamethasone Valerate | 11 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 11 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 11 | suppressed |
| Hydrocortisone | Hydrocortisone | 11 | suppressed |
| Indapamide | Indapamide | 11 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 11 | suppressed |
| Kapspargo Sprinkle | Metoprolol Succinate | 11 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 11 | suppressed |
| Nifedipine | Nifedipine | 11 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 11 | suppressed |
| Temazepam | Temazepam | 11 | suppressed |
| Ursodiol | Ursodiol | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,450.69 · 80 records | Novo Nordisk Inc | AIRSUPRA, AUSTEDO XR, BREZTRI, CAPLYTA, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, EVENITY, FARXIGA, INTERSTIM, JARDIANCE, KISUNLA, MOUNJARO, NEXLETOL, NURTEC ODT, OTEZLA, Ozempic, REPATHA, REXULTI, Rybelsus, TRELEGY ELLIPTA, TREMFYA, TRINTELLIX, UBRELVY, VOQUEZNA, Wegovy, ZAVZPRET, ZEPBOUND | 15 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error